Gastrointestinal stromal tumor (GIST) · line 1 · Imatinib (GIST advanced/metastatic 1L; KIT/PDGFRA imatinib-sensitive)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-IMATINIB-GIST-1L`

ID	`IND-GIST-1L-IMATINIB`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-GIST`
Sources	`SRC-IRIS-OBRIEN-2003` `SRC-NCCN-GIST-2025`

Notes

Standard 1L for the imatinib-sensitive GIST genotypes (~85% of all GIST). Reuses cross-line REG-IMATINIB-GIST-1L which encodes the KIT exon 9 dose-escalation rule.

Used By

Algorithms

ALGO-GIST-1L - ALGO-GIST-1L

Red flag

RF-GIST-PDGFRA-D842V - PDGFRA D842V substitution mutation in advanced or metastatic GIST. The PDGFRA D842V varia...